May 28, 2018 7:01 AM ET

Healthcare Providers and Services

Company Overview of IGeneX, Inc.

Company Overview

IGeneX, Inc. owns and operates a specialty immunology laboratory and research facility. It develops laboratory assays for Lyme and other tick-borne diseases. The company’s laboratory also functions as a pilot site for diagnostic manufacturers in the introduction of new assays. It serves private practice physicians, hospitals, and other clinical reference laboratories in the United States and Canada. IGeneX, Inc. was founded in 1991 and is based in Palo Alto, California.

795 San Antonio Road

Palo Alto, CA 94303

United States

Founded in 1991

Phone:

650-424-1191

Fax:

650-424-1196

Key Executives for IGeneX, Inc.

Compensation as of Fiscal Year 2017.

IGeneX, Inc. Key Developments

IGeneX, Inc. Introduces New Diagnostic Tests for Lyme Disease and Tick-Borne Relapsing Fever

IGeneX Inc. announced the launch of three new tests that are more inclusive and specific for aiding in diagnosis of Borreliosis (Lyme Disease and Tick-Borne Relapsing Fever, Borreliosis). Lyme ImmunoBlotIgM and IgG; Lyme ImmunoBlotIgM and IgGTBRF ImmunoBlot IgM and IgG; Lyme ImmunoBlotIgM and IgGTBRF ImmunoBlot IgM and IgGLyme IGX Spot; Lyme ImmunoBlotIgM and IgGTBRF ImmunoBlot IgM and IgGLyme IGX Spot. Lyme ImmunoBlots IgM and IgG: Although IGeneX Lyme Western blot prepared from Borrelia burgdorferi strains B31 and 297 is one of the most sensitive tests, it does not detect antibodies to all the B. burgdorferi sensu lato antigens. To develop all inclusive Western blots would be very expensive and impractical. Therefore, IGeneX has developed a Lyme ImmunoBlot that is very specific and inclusive of most species of B. burgdorferi sensu lato for clinical use with the following advantages over a Western blot: The specificity of the ImmunoBlot is 98.0% for IgM and 98.7% for IgG. This is higher than the traditional Western Blot; The 31kDa Epitope confirmation test will not be required on patient samples tested by Lyme ImmunoBlots; The sensitivity of the Lyme Immunoblot is 90.9% with well-defined samples. TBRF ImmunoBlots IgM and IgG: The TBRF ImmunoBlot is designed to detect antibodies to specific antigens of TBRF Borrelia in human serum. It detects antibodies to B. hermsii, B. miyamotoi, B. turicatae and B. coriaceae. Based on in-house studies these blots detect antibodies to North American, European and Australian strains of TBRF Borrelia in patient serum samples. The specificity of the TBRF ImmunoBlot is 94% and 98% for IgM and IgG respectively. Lyme IGX Spot: The LymeIGXSpot is an Enzyme-Linked ImmunoSpot (ELISPOT) assay that detects human T cells reactive to B. burgdorferi specific antigens in vitro. ELISPOT is a widely used method for detecting and monitoring cellular immune responses to specific antigens.

Similar Private Companies By Industry

Company Name Region
HealthQuest Physical Therapy and Medical Fitness United States
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IGeneX, Inc., please visit www.igenex.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.